Oxidative stress in pterygium: Relationship between p53 and 8-hydroxydeoxyguanosine

Molecular Vision

Volumn 12, Issue , 2006, Pages 1136-1142

  Perra, Maria Teresa ^a   Maxia, Cristina ^a   Corbu, Arianna ^a,b   Minerba, Luigi ^c   Demurtas, Paolo ^a   Colombari, Romano ^d   Murtas, Daniela ^a   Bravo, Sonia ^e   Piras, Franca ^a   Sirigu, Paola ^a,f  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c ASL8 ^*  (Italy)

^d City Hospital   (Italy)

^e UNIVERSIDAD DE CUENCA   (Ecuador)

^f Instituto Del Cncer de la Sociedad de Lucha Contra El Cncer (SOLCA)   (Ecuador)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; CELL DAMAGE; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL ARTICLE; COMPUTER PROGRAM; CONJUNCTIVA; CONJUNCTIVA EPITHELIUM; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DNA DAMAGE; FEMALE; FISHER EXACT TEST; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENOMIC INSTABILITY; GEOGRAPHIC DISTRIBUTION; HETEROZYGOSITY LOSS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MALE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PTERYGIUM; SIGNAL TRANSDUCTION; STAGING; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION;

ADULT; AGED; BIOLOGICAL MARKERS; DEOXYGUANOSINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OXIDATIVE STRESS; PTERYGIUM; STAINING AND LABELING; TISSUE DISTRIBUTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33749242812     PISSN: 10900535     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Taylor HR, West S, Munoz B, Rosenthal FS, Bressler SB, Bressler NM. The long-term effects of visible light on the eye. Arch Ophthalmol 1992; 110:99-104.
2. Di Girolamo N, Chui J, Coroneo MT, Wakefield D. Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Prog Retin Eye Res 2004; 23:195-228.
3. Peckar CO. The aetiology and histo-pathogenesis of pterygium. A review of the literature and a hypothesis. Doc Ophthalmol 1972; 31:141-57.
4. Vaughan D, Ashbury T. General ophthalmology. 8th ed. Los Altos (CA): Lange; 1977.
5. Coroneo MT. Albedo concentration in the anterior eye: a phenomenon that locates some solar diseases. Ophthalmic Surg 1990;21:60-6.
6. Moran DJ, Hollows FC. Pterygium and ultraviolet radiation: a positive correlation. Br J Ophthalmol 1984; 68:343-6.
7. Taylor HR, West SK, Rosenthal FS, Munoz B, Newland HS, Emmett EA. Corneal changes associated with chronic UV irradiation. Arch Ophthalmol 1989; 107:1481-4.
8. Threlfall TJ, English DR. Sun exposure and pterygium of the eye: a dose-response curve. Am J Ophthalmol 1999; 128:280-7.
9. Lin A, Stern G. Correlation between pterygium size and induced corneal astigmatism. Cornea 1998; 17:28-30.
10. Hirst LW. The treatment of pterygium. Surv Ophthalmol 2003; 48:145-80.
11. Grossniklaus HE, Green WR, Luckenbach M, Chan CC. Conjunctival lesions in adults. A clinical and histopathologic review. Cornea 1987; 6:78-116.
12. Perra MT, Maxia C, Zucca I, Piras F, Sirigu P. Immunohistochemical study of human pterygium. Histol Histopathol 2002; 17:139-49.
13. Saw SM, Tan D. Pterygium: prevalence, demography and risk factors. Ophthalmic Epidemiol 1999; 6:219-28.
14. Coroneo MT, Di Girolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol 1999; 10:282-8.
15. Detorakis ET, Drakonaki EE, Spandidos DA. Molecular genetic alterations and viral presence in ophthalmic pterygium. Int J Mol Med 2000; 6:35-41.
16. Tan DT, Tang WY, Liu YP, Goh HS, Smith DR. Apoptosis and apoptosis related gene expression in normal conjunctiva and pterygium. Br J Ophthalmol 2000; 84:212-6.
17. Sakoonwatanyoo P, Tan DT, Smith DR. Expression of p63 in pterygium and normal conjunctiva. Cornea 2004; 23:67-70.
18. Kria L, Ohira A, Amemiya T. Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium. Acta Histochem 1996; 98:195-201.
19. Kria L, Ohira A, Amemiya T. Growth factors in cultured pterygium fibroblasts: immunohistochemical and ELISA analysis. Graefes Arch Clin Exp Ophthalmol 1998; 236:702-8.
20. Di Girolamo N, Kumar RK, Coroneo MT, Wakefield D. UVB-mediated induction of interleukin-6 and -8 in pterygia and cultured human pterygium epithelial cells. Invest Ophthalmol Vis Sci 2002; 43:3430-7.
21. Liu Z, Xie Y, Zhang M. Overexpression of type I growth factor receptors in pterygium. Chin Med J (Engl) 2002; 115:418-21.
22. van Setten G, Aspiotis M, Blalock TD, Grotendorst G, Schultz G. Connective tissue growth factor in pterygium: simultaneous presence with vascular endothelial growth factor - possible contributing factor to conjunctival scarring. Graefes Arch Clin Exp Ophthalmol 2003; 241:135-9.
23. Marcovich AL, Morad Y, Sandbank J, Huszar M, Rosner M, Pollack A, Herbert M, Bar-Dayan Y. Angiogenesis in pterygium: morphometric and immunohistochemical study. Curr Eye Res 2002; 25:17-22.
24. Di Girolamo N, McCluskey P, Lloyd A, Coroneo MT, Wakefield D. Expression of MMPs and TIMPs in human pterygia and cultured pterygium epithelial cells. Invest Ophthalmol Vis Sci 2000; 41:671-9.
25. Pinkerton OD, Hokama Y, Shigemura LA. Immunologic basis for the pathogenesis of pterygium. Am J Ophthalmol 1984; 98:225-8.
26. Detorakis ET, Sourvinos G, Spandidos DA. Detection of herpes simplex virus and human papilloma virus in ophthalmic pterygium. Cornea 2001; 20:164-7.
27. Gallagher MJ, Giannoudis A, Herrington CS, Hiscott P. Human papillomavirus in pterygium. Br J Ophthalmol 2001; 85:782-4.
28. Piras F, Moore PS, Ugalde J, Perra MT, Scarpa A, Sirigu P. Detection of human papillomavirus DNA in pterygia from different geographical regions. Br J Ophthalmol 2003; 87:864-6.
29. Clear AS, Chirambo MC, Hutt MS. Solar keratosis, pterygium, and squamous cell carcinoma of the conjunctiva in Malawi. Br J Ophthalmol 1979; 63:102-9.
30. Dushku N, Reid TW. P53 expression in altered limbal basal cells of pingueculae, pterygia, and limbal tumors. Curr Eye Res 1997; 16:1179-92.
31. Tan DT, Lim AS, Goh HS, Smith DR. Abnormal expression of the p53 tumor suppressor gene in the conjunctiva of patients with pterygium. Am J Ophthalmol 1997; 123:404-5.
32. Mackenzie FD, Hirst LW, Battistutta D, Green A. Risk analysis in the development of pterygia. Ophthalmology 1992; 99:1056-61.
33. Cullen AP. Photokeratitis and other phototoxic effects on the cornea and conjunctiva. Int J Toxicol 2002; 21:455-64.
34. Kau HC, Tsai CC, Lee CF, Kao SC, Hsu WM, Liu JH, Wei YH. Increased oxidative DNA damage, 8-hydroxydeoxy- guanosine, in human pterygium. Eye 2006; 20:826-831.
35. Wong TY, Foster PJ, Johnson GJ, Seah SK, Tan DT. The prevalence and risk factors for pterygium in an adult Chinese population in Singapore: the Tanjong Pagar survey. Am J Ophthalmol 2001; 131:176-83.
36. Bruner SD, Norman DP, Verdine GL. Structural basis for recognition and repair of the endogenous mutagen 8-oxoguanine in DNA. Nature 2000; 403:859-66.
37. Ichihashi M, Ueda M, Budiyanto A, Bito T, Oka M, Fukunaga M, Tsuru K, Horikawa T. UV-induced skin damage. Toxicology 2003; 189:21-39.
38. Tsai YY, Cheng YW, Lee H, Tsai FJ, Tseng SH, Lin CL, Chang KC. Oxidative DNA damage in pterygium. Mol Vis 2005; 11:71-5.
39. Reisman D, McFadden JW, Lu G. Loss of heterozygosity and p53 expression in Pterygium. Cancer Lett 2004; 206:77-83.
40. Dushku N, Hatcher SL, Albert DM, Reid TW. p53 expression and relation to human papillomavirus infection in pingueculae, pterygia, and limbal tumors. Arch Ophthalmol 1999; 117:1593-9.
41. Chowers I, Pe'er J, Zamir E, Livni N, Ilsar M, Frucht-Pery J. Proliferative activity and p53 expression in primary and recurrent pterygia. Ophthalmology 2001; 108:985-8.
42. Ueda Y, Kanazawa S, Kitaoka T, Dake Y, Ohira A, Ouertani AM, Amemiya T. Immunohistochemical study of p53, p21 and PCNA in pterygium. Acta Histochem 2001; 103:159-65.
43. Weinstein O, Rosenthal G, Zirkin H, Monos T, Lifshitz T, Argov S. Overexpression of p53 tumor suppressor gene in pterygia. Eye 2002; 16:619-21.
44. Shimmura S, Ishioka M, Hanada K, Shimazaki J, Tsubota K. Telomerase activity and p53 expression in pterygia. Invest Ophthalmol Vis Sci 2000; 41:1364-9.
45. Onur C, Orhan D, Orhan M, Dizbay Sak S, Tulunay O, Irkec M. Expression of p53 protein in pterygium. Eur J Ophthalmol 1998; 8:157-61.
46. Palozza P, Serini S, Di Nicuolo F, Boninsegna A, Torsello A, Maggiano N, Ranelletti FO, Wolf FI, Calviello G, Cittadini A. beta-Carotene exacerbates DNA oxidative damage and modifies p53-related pathways of cell proliferation and apoptosis in cultured cells exposed to tobacco smoke condensate. Carcinogenesis 2004; 25:1315-25.
47. Kim SY, Kim DS, Kwon SB, Park ES, Huh CH, Youn SW, Kim SW, Park KC. Protective effects of EGCG on UVB-induced damage in living skin equivalents. Arch Pharm Res 2005; 28:784-90.
48. Nishigori C. Cellular aspects of photocarcinogenesis. Photochem Photobiol Sci 2006; 5:208-14.
49. Nolan TM, DiGirolamo N, Sachdev NH, Hampartzoumian T, Coroneo MT, Wakefield D. The role of ultraviolet irradiation and heparin-binding epidermal growth factor-like growth factor in the pathogenesis of pterygium. Am J Pathol 2003; 162:567-74.
50. Pierceall WE, Goldberg LH, Tainsky MA, Mukhopadhyay T, Ananthaswamy HN. Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog 1991; 4:196-202.
51. Seidl H, Kreimer-Erlacher H, Back B, Soyer HP, Hofler G, Kerl H, Wolf P. Ultraviolet exposure as the main initiator of p53 mutations in basal cell carcinomas from psoralen and ultraviolet A-treated patients with psoriasis. J Invest Dermatol 2001; 117:365-70. Erratum in: J Invest Dermatol 2001; 117:1688.
52. Sabattini E, Bisgaard K, Ascani S, Poggi S, Piccioli M, Ceccarelli C, Pieri F, Fraternali-Orcioni G, Pileri SA. The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol 1998; 51:506-11.
53. Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J Immunol Methods 1989; 125:279-85.
54. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-31.
55. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2:594-604.
56. Beroud C, Soussi T. The UMD-p53 database: new mutations and analysis tools. Hum Mutat 2003; 21:176-81.
57. Schneider BG, John-Aryankalayil M, Rowsey JJ, Dushku N, Reid TW. Accumulation of p53 protein in pterygia is not accompanied by TP53 gene mutation. Exp Eye Res 2006; 82:91-8.
58. Tsai YY, Cheng YW, Lee H, Tsai FJ, Tseng SH, Chang KC. P53 gene mutation spectrum and the relationship between gene mutation and protein levels in pterygium. Mol Vis 2005; 11:50-5.
59. Goukassian DA, Bagheri S, el-Keeb L, Eller MS, Gilchrest BA. DNA oligonucleotide treatment corrects the age-associated decline in DNA repair capacity. FASEB J 2002; 16:754-6.
60. Perra MT, Colombari R, Maxia C, Zucca I, Piras F, Corbu A, Bravo S, Scarpa A, Sirigu P. Finding of conjunctival melanocytic pigmented lesions within pterygium. Histopathology 2006; 48:387-93.
61. Jakobiec FA, Folberg R, Iwamoto T. Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva. Ophthalmology 1989; 96:147-66.